Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

n thousands, except per share information)(Unaudited)Three Months EndedSix Months EndedJune 30, June 30,2014201320142013Revenue:Product sales and royalty revenue

$
5,891
$
,675
$
,808
$
22,810
Non-cash royalty revenue related to sale of future royalties

4,8373,82810,6108,221License, collaboration and other revenue

17,78519,35925,86625,835Total revenue28,51333,86248,28456,866Operating costs and expenses:Cost of goods sold5,1085,01113,01516,672Research and development36,70252,23075,04097,848General and administrative9,6199,22619,54720,057Total operating costs and expenses

51,42966,467107,602134,577Loss from operations(22,916)(32,605)(59,318)

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Stryker Orthopaedics, the ... Champions Tour, is rounding out its debut year of ... Scottsdale, AZ. This marks the ... Champions Tour that the brand has activated on-site with ... educate golf fans on the importance of joint health.  ...
(Date:10/30/2014)... Oct. 30, 2014  Electronic health records uptake ... result of government initiatives and the considerable resources ... have invested over the past five years. Electronic ... IT, and U.S. clinicians use them on a ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & Sullivan,s ...
(Date:10/30/2014)... , Oct. 30, 2014 Molecular Profiles Ltd., ... CBRX ) and Maryland -based Xceleron ... improved efficiency during clinical development that will be launched ... next week. This partnership extends Molecular Profiles, ... it launched earlier this month. The company also has ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... 2012 Sorbent Therapeutics, Inc. a biopharmaceutical company developing ... from its Phase 2a clinical study of CLP1001.  In ... kidney disease, CLP1001 demonstrated improvement in heart failure symptoms ... the randomized, double-blind Phase 2a study were presented in ...
...  Eli Lilly and Company (NYSE: LLY ) ... 1 (GLP-1) analog being studied as a once-weekly treatment ... non-inferiority for mean 24-hour systolic blood pressure (SBP, or ... results came from a Phase II study that compared ...
Cached Medicine Technology:Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 2Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 3Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 2Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 3Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 4
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 REV'D Provision ... are now available through a unique service called, ... designed to empower the everyday athlete. The Feed has ... athletes and created a system to pass that information ... see REV’D® is now available on The Feed!” says ...
(Date:10/30/2014)... Victory Healthcare, a privately owned ... quarter infection rates and patient satisfaction scores. The ... only two percent or less, and the medical ... percent. , “We are delighted with our strong ... scores,” said Robert Helms, chairman and CEO of ...
(Date:10/30/2014)... (HealthDay News) -- Scientists who used stem cells to ... breakthrough could provide a new way to learn more ... The team used human pluripotent stem cells -- which ... -- to grow the functional miniature stomachs, to study ... cause of ulcers and stomach cancer. The miniature ...
(Date:10/30/2014)... (HealthDay News) -- Many U.S. colleges have indoor ... tanning increases the risk for skin cancer, researchers ... particularly white women, so colleges should adopt tanning-free ... said. "Public health efforts are needed to ... the harms that indoor tanning poses to young ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2
... risk of hypertension, hardening of arteries , , FRIDAY, May 15 ... harbor could be a cause of high blood pressure, animal ... likely to develop not only high blood pressure but also ... report in the May 15 issue of PLoS Pathogens ...
... Boston Scientific Corporation (NYSE: BSX ) ... news announcements at the annual EuroPCR Scientific Program, which ... are pleased to be announcing additional analyses from the ... outcomes, as well as insights on the design and ...
... ATLANTA, May 15 Paul Capital Healthcare today announced ... a panel on non-traditional forms of financing at the ... with how to evaluate non-dilutive financing options that can ... development, the panel, "Non-dilutive and Other Non-traditional Forms of ...
... establish Group B Strep colonization of pregnant women and ... newbornsGBS PNA FISH shown to detect up to 42% ... and VEDBAEK, Denmark, May 15 AdvanDx today announced ... for detection of Streptococcus agalactiae , aka Group ...
... May 15 Endocare, Inc. (Nasdaq: ENDO ... development of minimally invasive technologies used by urologists and ... results for the first quarter ended March 31, 2009. ... increase in revenue and strong margins.Total revenues for the ...
... 400umol/g delivers Market Leading Economies to Reduce Synthesis Costs and ... ... (PRWEB) May 15, 2009 -- Kinovate Life Sciences, Inc, the ... announcing the successful development of its next generation high loading ...
Cached Medicine News:Health News:Viral Infection Might Trigger High Blood Pressure 2Health News:Viral Infection Might Trigger High Blood Pressure 3Health News:Boston Scientific Announces Schedule for EuroPCR 2009 2Health News:Boston Scientific Announces Schedule for EuroPCR 2009 3Health News:Boston Scientific Announces Schedule for EuroPCR 2009 4Health News:Boston Scientific Announces Schedule for EuroPCR 2009 5Health News:Boston Scientific Announces Schedule for EuroPCR 2009 6Health News:Paul Capital Healthcare to Participate in Panel on Non-Traditional Forms of Financing 2Health News:AdvanDx Receives FDA 510(k) Clearance for GBS PNA FISH(R) for Rapid Detection of Group B Strep from Lim Broths 2Health News:AdvanDx Receives FDA 510(k) Clearance for GBS PNA FISH(R) for Rapid Detection of Group B Strep from Lim Broths 3Health News:Endocare Reports 2009 First Quarter Financial Results 2Health News:Endocare Reports 2009 First Quarter Financial Results 3Health News:Endocare Reports 2009 First Quarter Financial Results 4Health News:Endocare Reports 2009 First Quarter Financial Results 5Health News:Endocare Reports 2009 First Quarter Financial Results 6Health News:Endocare Reports 2009 First Quarter Financial Results 7Health News:Endocare Reports 2009 First Quarter Financial Results 8Health News:Endocare Reports 2009 First Quarter Financial Results 9Health News:Endocare Reports 2009 First Quarter Financial Results 10Health News:Endocare Reports 2009 First Quarter Financial Results 11Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 2Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 3Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 4
... Rusch Snap-Light™ laryngoscope blades are designed with ... fiber optic bundle can be removed to ... to reach areas. Our unique snap-on mechanism ... bright focused blades are interchangeable with other ...
... high quality fiberoptic system designed to meet ... fiberoptic laryngoscopes. The green color coding identifies ... to interconnect with other green coded systems. ... bright and focused light. The Greenspec pivot ...
Rigid plastic. Single use. Non-Sterile. The disposable laryngoscope blade that fits on a standard handle. Made of extremely rigid plastic. Bright white light out-performs metal blades. Single patient...
... Laryngoscopes are a high quality fiberoptic system ... greater standardization to fiberoptic laryngoscopes. The green ... indicates it's ability to interconnect with other ... offers a cool, bright and focused light. ...
Medicine Products: